Skip to main content Skip to search Skip to main navigation

EMA: Guiding Principles on LLMs, a Category of Generative AI

On 5 September 2024 the EMA and the Heads of Medicine Agencies HMA, published guiding principles that set how EU medicine regulators can use large language models (LLMs), a form of generative AI, focusing on text generation in regulatory science and for regulatory activities. The 10-page document provides high-level recommendations to facilitate LLMs' safe, responsible, and effective use, being of interest to anyone who uses or would like to use such AI models in the future.

"LLMs have enormous transformative potential," says EMA, “but also present challenges: variability in results, returning of irrelevant or inaccurate responses (so-called hallucinations), and potential data security risks." On the other hand, LLMs could be applied to query the extensive documentation regulators receive, to automate knowledge/data mining processes, or as virtual AI assistants in everyday administrative tasks.

Therefore, the document aims to build an understanding of the capabilities and limitations of these applications among staff at regulatory agencies across the EU to harness the potential of LLMs effectively and avoid pitfalls and risks. General ethical considerations, e.g. the rule of law, accountability, security, safety, transparency, non-discrimination, misinformation harms, and malicious uses or copyright issues are included.

Being part of the multiannual AI work plan to 2028 set out by EMA, the guiding principles are considered a living document that will be regularly updated. An EMA factsheet on LLMs can be found here.


Source:

EMA: Guiding principles on the use of LLMs in regulatory science and for medicines regulatory activities

EMA: Factsheet on the 4 principles for safe and responsible use of LLMs

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next